Aarti Drugs Ltd.
Microcap 250
₹428.50
-1.95%
Delayed · cached 15 min
Fair value analysis
AARTIDRUGS
Aarti Drugs Ltd.
₹437.00
Close used for this calculation
₹393.46Fair value
Financial DNA Score
Profitability · Returns · Balance Sheet · Efficiency · Growth
48/100
Quality radar
Consensus fair value
₹393.46
Near FV▼ -10.0% against the close used
Model range ₹126.02 – ₹762.55
The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.
Price target range & 52-week position
Bear₹126.02Fair value₹393.46Bull₹762.55
FairClose
52-week traded range
52W low ₹319.7552W high ₹525.35
The 52-week range is measured from the stored price history, not estimated.
Valuation summary
Trading above the consensus fair value
Aarti Drugs Ltd. closed at ₹437.00, 11.1% above the consensus fair value of ₹393.46 drawn from 9 valuation models.
Financial DNA score 48/100 — Average. P/E of 20.3x against the 20x sector multiple the P/E model uses.
Quantitative summary only — not investment advice.
All valuation models
DCF Valuation
₹148.48
-66.0%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=5.9%, r=10%, tg=3%, n=10yr
Graham Number
₹286.99
-34.3%
√(22.5 × EPS × BVPS)
EPS=21.36, BVPS=171.37 · outside Graham range (P/E 20.3, P/B 2.6) — asset-light, treat as a rough floor
Graham Formula
₹402.64
-7.9%
EPS × (8.5 + 2g) × 6.5 ÷ FD_Rate
g=5.9%, FD=7%
P/E Fair Value
₹762.55
+74.5%
EPS × 35.7x (sector P/E)
EPS=21.36, Sector P/E=35.7x
Peter Lynch (PEG)
₹126.02
-71.2%
EPS × Growth% (PEG = 1 is fair)
EPS=21.36, g=5.9%
EV/EBITDA
₹483.93
+10.7%
(EBITDA × 13x − Net Debt) ÷ Shares
EBITDA=3.79B
Book Value (P/B)
₹313.49
-28.3%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=171.37, ROE=13.4%, g=5.9%, r=10%
Reverse DCF
₹437.00
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: 7.5% | Historical: 5.9%
Margin of Safety
₹300.12
-31.3%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=400.16, MoS=25%
Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.
Educational data only. Not a recommendation to buy, sell or hold any security.